193 results about "Fibrinolysis" patented technology

A catheter including a main body having a first end, a second end, a lumen extending between the first end and the second end, a first section located proximal the first end of the main body and second section located proximal the second end of the main body. An inhibitory polymer is disposed at the first section. The inhibitory polymer includes one or more members selected from the group consisting of antiproliferatives, antithrombotics, thrombolytics, and fibrinolytics. An antimicrobial agent is disposed at the second section. The main body has a length such that when the catheter is at least partially implanted the first end accesses a body vessel and at least a portion of the second section is disposed within a subcutaneous space of a patient.

A removable filter for capturing thrombi in a body vessel. The filter has anti-thrombogenic, echogenic, and radiopaque features. The features of the filter provide for enhanced identifying and reduced endotheliosis in a body vessel of a patient. Generally, the anti-thrombogenic feature is preferably a fibrinolytic coating disposed on the filter to decrease the accumulation of fibrin thereon. The echogenic feature preferably is comprised of marks formed on the filter that give rise to reflections of ultrasound waves during ultrasonography. The radiopaque feature is preferably a polymeric coating, ceramic coating, or noble metal coating applied on the filter for enhanced fluoroscopy.

The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.

The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.

The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.

The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.

Device, method, and computer program product for determining a material parameter of a blood coagulation cascade based on parameters of light diffused at a biofluid sample. In one example, the biofluid sample includes a blood sample. Laser light scattered by the sample is collected by the optical system in reflection and / or transmission mode. An image of the sample in so collected light is formed, and data representing fluctuations of laser speckle intensity with is processed to derive numerical descriptors associated with blood coagulation and fibrinolysis. In a specific case, such numerical descriptors are derived based on temporal dynamic of a viscoelastic characteristic of the blood sample.

The present invention is a method of extracting infectious pathogens from a volume of blood including the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The fibrin lysis reagent is preferably composed of plasminogen and streptokinase frozen in coincident relation until the fibrin lysis reagent is needed whereby streptokinase enzymatically reacts with plasminogen to form plasmin upon thawing. The plasminogen is suspended in an aqueous salt solution prior to freezing including NaCl and Na3PO4.

The invention relates to detecting coagulation and coagulation-related activities including agglutination and fibrinolysis of samples. More particularly the invention relates to methods and apparatus for monitoring coagulation and / or obtaining a coagulation time of a sample using NMR-based detectors.

Described is use of Salvia hispanica L. (Chia) for controlling, in one embodiment reducing, blood glucose levels, preferably post-prandial blood glucose levels. This is useful in both non-diabetic and diabetic individuals, but especially in diabetic individuals. Also described is the use of chia in reducing postprandial blood glucose, insulin sensitivity, blood pressure, and oxidative stress in such individuals. The present invention further found that Chia can be used to improve endothelial function, coagulation, fibrinolysis and iron status. The present invention further encompasses the use of Chia in the treatment and / or management of diabetes and / or the treatment and management of diabetes associated conditions or risk factors, such as one or more of the following: blood pressure and blood glucose levels, post-prandial glycemia, inflammatory factors (C-reactive protein), coagulation (fibrinogen, factor VIII, von Willenbrand factor), and fibronolytic factors (such as t-PA), iron status and endothelial function, (such as increase in nitric oxide generation). In one embodiment the invention relates to dietary approaches to such treatment and management.

Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.

The present invention relates to a nanometer biological robot. The nanometer robot is driven by molecular motors and guided by thrombus antibodies to assist in quickly dissolving thrombi. The rapid rotation of the molecular motors on partial thrombi produces the effect similar to that of a micro power agitator. The molecular motors are driven by light, so the nanometer biological robot is adjustable and controllable. The contact of drugs with fiber proteins is accelerated, the biological and machinery mechanics effect of the nanometer biological robot is synergetic with the medical enzymolysis, and the fibrinolysis is accelerated.

Compositions and methods for targeting substances to fibrinogen, fibrin monomers, or fibrin polymers are provided. These compositions and methods generally involve the use of fibrin knob peptides that bind fibrin(ogen), which can be used to detect fibrin(ogen) and modulate fibrin polymerization and fibrinolysis.

The invention relates to a preparation method for a liquid thrombin time (TT) detection reagent, which also comprises main components of the liquid thrombin time (TT) detection reagent. The TT is a simple and convenient test for detecting functions of coagulation, anticoagulation and a fibrinolytic system, is widely used for monitoring and treating high molecular weight heparin and treating fibrinolysis, and for screening fibrinogen disorder and some fibrinogen deficiency symptoms and has significance on various clinic disease diagnoses. The preparation method for the liquid thrombin time (TT)detection reagent adopts a bovine thrombin as a main material and adopts a unique stabilization system to prepare a novel liquid thrombin time (TT) detection reagent. The novel stabilization system solves the difficult problem of maintaining the stability of a reagent in a liquid state, and has the advantages of high sensitivity, convenient use, small experiment error, strong stability, good compatibility, low cost and the like.

Compositions and methods for targeting substances to fibrinogen, fibrin monomers, or fibrin polymers are provided. These compositions and methods generally involve the use of fibrin knob peptides that bind fibrin(ogen), which can be used to detect fibrin(ogen) and modulate fibrin polymerization and fibrinolysis.

Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.

A functional mutant of human plasminogen disclosed in the invention, respectively, is hPLG-delta K: human plasminogen protein Pro<544>-Asn<791> polypeptide; Pro<559> in RGD-hPLG-delta K: hPLG-delta K is mutated to Asp<559>; and Gly<560> in RHP-hPLG-delta K: hPLG-delta K polypeptide is mutated to His<560>. The invention also discloses a preparation method for the functional mutant. The product is obtained by using a plasmid containing a full-length cDNA sequence of human plasminogen as a template to carry out a PCR to construct a plasmid and using Pichia Pastoris expression. The functional mutant has a dual-function of fibrinolysis and inhibiting platelet aggregation or inhibiting fibrin monomer polymerization.

The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministrating an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.

The present invention is directed to a compound of formula I:or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.

The invention discloses a high-frequency electrosurgical operation instrument, which comprises a high-frequency generator and is characterized in that the high-frequency generator consists of a control circuit, a radio-frequency output circuit and a display circuit, wherein the radio-frequency output circuit is connected with an operation electrode, and the operation electrode and the control circuit form a control loop. By using the high-frequency electrical energy output by a main machine and combining the pressure of a vascular forceps port, collagen and fibrin in human tissues are dissolved and denatured, and vascular walls are fused to form a transparent zone so as to form permanent obliteration. No matter open operation or operation under an endoscope, the operation instrument can fully play a role in any vein, artery or tissue bundle with diameter of within 7 millimeters, and is safer, quicker and more convenient to close or cut the vein, the artery or the tissue bundle. An ultrasonic cutting hemostasis knife is difficult to achieve the advantages.

The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, or prolonging the half lives of the fibrinolytic agents by adding EEIIMD.

The invention provides a bacterial strain LT3 producing alkaline cellulose and a breeding method and an initial optimization of cellulose production conditions thereof. The bacterial strain LT3 with higher secretory volume of alkaline cellulose is obtained by steps of conducting accumulation culture, separation and purification, identification of Congo red dye and liquid fermentation on samples obtained from rotten wood or nearby soil thereof; the bacterial strain is identified to be bacillus cereus by initial identification, sequence clone and phylogenetic analysis; and 16s and r DNA sequences are shown as sequence list SEQ ID NO.1. The invention has potential theoretical and application values for research on the action mechanism of the alkaline cellulose and the production of the alkaline cellulose preparation; and the bacterial strain LT3 of the alkaline cellulose can produce the alkaline cellulose of single component and is convenient for separation and purification, thus being an ideal material for gene clone of the alkaline cellulose and having potential theoretical and practical significances for constructing alkaline cellulose fibrinolysis engineered bacterial strain and questing the action mechanism of the alkaline cellulose, and the method is simple, fast and easy for implementation.

The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.

The invention relates to a blood coagulation factor and fibrinolysis measuring method, which is used for testing by using a semi-automatic blood coagulation analyzer. The blood coagulation factor and fibrinolysis measuring method comprises the following testing steps of: collecting a patient blood sample and separating blood plasma out; injecting the blood plasma into a testing cup by using a sample feeding gun; putting the testing cup in a blood coagulation factor measuring device, adding a reagent, starting a timing button of the blood coagulation factor testing device, and testing the blood plasma in the testing cup by the blood coagulation factor testing device according to a double magnetic circuit magnetic bead method; and injecting the blood plasma into a fibrinolysis testing cup by the sample feeding gun, putting the fibrinolysis testing cup in a fibrinolysis testing device, adding a reagent, starting a timing button of the fibrinolysis testing device, testing the blood plasmain the fibrinolysis testing cup by the fibrinolysis testing device according to a photoelectric turbidimetry, and printing and outputting fibrinolysis data after the testing by the fibrinolysis testing device is ended. The blood coagulation factor and fibrinolysis measuring method disclosed by the invention is simple and convenient and greatly reduced in cost.

The invention discloses a traditional Chinese compound preparation for curing nonalcoholic fatty liver and central obesity and is characterized in that the compound preparation is prepared by adding medicinal excipient to the extractives of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris, wherein the weight mixture ratio of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris is 1-4:1:1-3:1-3:1-3. Proved by clinical trial, the drug combination of the invention can reduce the abdominal perimeter of patients, lower the AUC (area under curve) of triglyceride after dinner, improve the CT specific value of liver and spleen and bring down the transaminase level of liver with evident treatment effect. Verified by clinical research, the compound can obviously increase the insulin sensitivity of patients, lower inflammatory factor level and improve fibrinolysis-blood clotting function. Shown by experimental research, the drug of the invention can enhance the sensitivity of fat and muscle cells to insulin and has significant value in treating nonalcoholic fatty liver and central obesity which take insulin resistance as fundamental pathological link.

The invention relates to the field of wine making, and particularly relates to strains with high cellulase activity as well as a screening method and a use method of the strains. The strains with high cellulase activity are aspergillus. The screening method comprises the following steps of: A. enriching and cultivating bacteria through an inorganic salt culture medium; B. carrying out once or multiple-time inoculation on the bacteria enriched and cultivated on filter paper dipped with the inorganic salt culture medium; C. acquiring a cultured product at the fracture part of the filter paper, and carrying out once or multiple-time streaking on the cultured product on a carboxymethylcellulose culture medium plate, so as to obtain pure strains; D. cultivating the pure strains obtained from the step C in the inorganic salt culture medium and carrying out fibrinolysis on the cultivated pure strains; E. inoculating the pure strains with high fibrinolysis capacity in the step D to a steriled solid fermentation medium for cultivating; and F. extracting coarse enzyme liquid by adopting a water bath method, and carrying out enzyme activity test to obtain the strains with high cellulase activity. The strains and bread yeast are compounded for use and fermented by taking wine waste lees and brans as main materials. With the adoption of the strains with high cellulase activity, the fermentation rate of the wine waste lees can be improved.

The invention discloses a traditional Chinese medicine preparation for purifying blood, which comprises the following components: hawthorn, Astragalus root, leech, cortex moutan, safflower, hemlock parsley, suberect spatholobus stem, vinegar-radix paeoniae alba, angelica, trogopterus dung, salviae miltiorrhizae, propolis, calendula officinalis root, ginkgo leaf and gynostemma pentaphylla. The traditional Chinese medicine composite has the obvious effect of reducing blood lipid, can promote the decomposition of blood lipid, reduces blood viscosity, and resists atherosclerosis; the traditional Chinese medicine composite has the obvious effects of anticoagulation and anti-thrombosis, can inhibit the aggregation of thrombocyte, improves the activity of plasmin, and promotes fibrinolysis; the traditional Chinese medicine composite has favorable effects of heart strengthening, decompression and arrhythmia resistance, can slow heart rate, dilates coronary artery and blood vessel of brain, increases blood flow, lightens myocardial ischemic injury degree, lowers myocardial oxygen consumption, has obvious prevention effect on ischemic cerebrovascular diseases, can dilate peripheral vessel, reduces vascular resistance and promotes blood circulation; and the traditional Chinese medicine composite can promote the generation of haemoglobin and erythrocyte.

The invention discloses a eupolyphaga seu steleophaga small-peptide chelate capable of facilitating fibrinolysis and a preparation method thereof, and belongs to the biotechnology field. The preparation method is characterized in that eupolyphaga seu steleophaga serves as the starting material, enzymolysis, ultrafiltration, resin column purification, chelating reaction and drying are conducted, the eupolyphaga seu steleophaga small-peptide chelate is obtained, and a corresponding preparation can be prepared by adding preparation auxiliaries through a conventional method. The eupolyphaga seu steleophaga small-peptide chelate has higher fibrinolysis facilitating activity and has the advantages of being free of toxic and side effects, free of pesticide damage, low in cost and the like.